<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anaphylaxis in adults: Rapid overview of emergency management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anaphylaxis in adults: Rapid overview of emergency management</h1>
<div class="graphic"><div class="figure"><div class="ttl">Anaphylaxis in adults: Rapid overview of emergency management</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Diagnosis is made clinically:</td> </tr> <tr> <td class="indent1">The most common signs and symptoms are cutaneous (eg, sudden onset of generalized urticaria, angioedema, flushing, pruritus). However, 10 to 20% of patients have no skin findings.</td> </tr> <tr> <td class="indent1 red"><strong>Danger signs – Rapid progression of symptoms, respiratory distress (eg, stridor, wheezing, dyspnea, increased work of breathing, persistent cough, cyanosis), vomiting, abdominal pain, hypotension, dysrhythmia, chest pain, collapse.</strong></td> </tr> <tr> <td class="subtitle1_single">Acute management:</td> </tr> <tr> <td class="indent1">The first and most important treatment in anaphylaxis is epinephrine. There are <strong>NO absolute contraindications to epinephrine</strong> in the setting of anaphylaxis.</td> </tr> <tr> <td class="indent1"><strong>Airway –</strong> Immediate intubation if evidence of impending airway obstruction from angioedema. Delay may lead to complete obstruction. Intubation can be difficult and should be performed by the most experienced clinician available. Cricothyrotomy may be necessary.</td> </tr> <tr> <td class="subtitle2_single">Promptly and simultaneously, give:</td> </tr> <tr> <td class="indent2"><strong>IM epinephrine (1 mg/mL preparation) –</strong> Give epinephrine 0.3 to 0.5 mg IM in the mid-outer thigh. Can repeat every 5 to 15 minutes (or more frequently), as needed. If epinephrine is injected promptly IM, most patients respond to 1, 2, or at most, 3 doses. If symptoms are not responding to epinephrine injections, prepare IV epinephrine for infusion (refer to below).</td> </tr> <tr> <td class="indent2"><strong>Place patient in recumbent position</strong>, if tolerated, and elevate lower extremities.</td> </tr> <tr> <td class="indent2"><strong>Oxygen –</strong> Give with nonrebreather mask at 15 liters/minute flow rate or commercial high-flow oxygen masks (providing at least 70% and up to 100% oxygen), as needed.</td> </tr> <tr> <td class="indent2"><strong>Normal saline rapid bolus –</strong> Treat hypotension with rapid infusion of 1 to 2 liters IV. Repeat, as needed. Massive fluid shifts with severe loss of intravascular volume can occur. Monitor urine output.</td> </tr> <tr> <td class="indent2"><strong>Albuterol (salbutamol) –</strong> For bronchospasm resistant to IM epinephrine, give 2.5 to 5 mg in 3 mL saline via nebulizer, or 2 to 3 puffs by metered dose inhaler. Repeat, as needed.</td> </tr> <tr> <td class="subtitle2_single">Adjunctive therapies:</td> </tr> <tr> <td class="indent2"><strong>H1 antihistamine</strong><sup>*</sup> <strong>–</strong> Consider giving cetirizine 10 mg IV (given over 2 minutes) or diphenhydramine 25 to 50 mg IV (given over 5 minutes) – for relief of urticaria and itching only.</td> </tr> <tr> <td class="indent2"><strong>H2 antihistamine</strong><sup>*</sup> <strong>–</strong> Consider giving famotidine 20 mg IV (given over 2 minutes).</td> </tr> <tr> <td class="indent2"><strong>Glucocorticoid</strong><sup>*</sup> <strong>–</strong> Consider giving methylprednisolone 125 mg IV.</td> </tr> <tr> <td class="indent2"><strong>Monitoring –</strong> Continuous noninvasive hemodynamic monitoring and pulse oximetry monitoring should be performed. Urine output should be monitored in patients receiving IV fluid resuscitation for severe hypotension or shock.</td> </tr> <tr> <td class="subtitle1_single">Treatment of refractory symptoms:</td> </tr> <tr> <td class="indent1"><strong>Epinephrine infusion</strong><sup>¶</sup> <strong>–</strong> For patients with inadequate response to IM epinephrine and IV saline, give epinephrine continuous infusion, beginning at <strong>0.1 microgram/kg/minute</strong> by infusion pump<sup>Δ</sup>. Titrate the dose continuously according to blood pressure, cardiac rate and function, and oxygenation.</td> </tr> <tr> <td class="indent1"><strong>Vasopressors</strong><sup>¶</sup> <strong>–</strong> Some patients may require a second vasopressor (in addition to epinephrine). All vasopressors should be given by infusion pump, with the doses titrated continuously according to blood pressure and cardiac rate/function and oxygenation monitored by pulse oximetry.</td> </tr> <tr> <td class="indent1"><strong>Glucagon –</strong> Patients on beta blockers may not respond to epinephrine and can be given glucagon 1 to 5 mg IV over 5 minutes, followed by infusion of 5 to 15 micrograms/minute. Rapid administration of glucagon can cause vomiting.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Instructions on how to prepare and administer epinephrine for IV continuous infusions are available as separate tables in UpToDate.</div><div class="graphic_footnotes"><p>IM: intramuscular; IV: intravenous.</p>
<p>* These medications should not be used as initial or sole treatment.</p>
<p>¶ All patients receiving an infusion of epinephrine and another vasopressor require continuous noninvasive monitoring of blood pressure, heart rate and function, and oxygen saturation.</p>
    
    Δ For example, the initial infusion rate for a 70 kg patient would be 7 micrograms/minute. This is consistent with the recommended range for non-weight-based dosing for adults, which is 2 to 10 micrograms/minute. Non-weight-based dosing can be used if the patient's weight is not known and cannot be estimated.</div><div class="graphic_reference">Adapted from: Simons FER. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.</div><div id="graphicVersion">Graphic 58346 Version 36.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
